Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have been assigned an average recommendation of “Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $38.00.
Several research analysts recently issued reports on NTLA shares. Barclays upped their price target on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 7th. JMP Securities started coverage on shares of Intellia Therapeutics in a research report on Thursday, March 8th. They set an “outperform” rating on the stock. Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a research report on Wednesday, March 14th. Chardan Capital upgraded shares of Intellia Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Finally, ValuEngine upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.
Shares of NASDAQ:NTLA traded down $0.39 on Monday, hitting $25.26. The stock had a trading volume of 23,885 shares, compared to its average volume of 1,049,812. Intellia Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.99. The company has a market capitalization of $1.06 billion, a PE ratio of -13.75 and a beta of 3.21.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, May 1st. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.07. Intellia Therapeutics had a negative net margin of 278.64% and a negative return on equity of 31.80%. The company had revenue of $7.47 million for the quarter, compared to the consensus estimate of $6.14 million. equities research analysts predict that Intellia Therapeutics will post -2 earnings per share for the current fiscal year.
In other Intellia Therapeutics news, insider John M. Leonard sold 8,400 shares of the business’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $24.00, for a total transaction of $201,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jean Francois Formela sold 6,686 shares of the business’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $25.04, for a total value of $167,417.44. The disclosure for this sale can be found here. Insiders have sold a total of 54,331 shares of company stock valued at $1,305,796 over the last three months. Company insiders own 3.20% of the company’s stock.
A number of large investors have recently made changes to their positions in NTLA. Farallon Capital Management LLC bought a new stake in Intellia Therapeutics during the 4th quarter worth about $21,911,000. ARK Investment Management LLC raised its holdings in Intellia Therapeutics by 269.2% during the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after purchasing an additional 1,002,671 shares during the last quarter. Federated Investors Inc. PA raised its holdings in Intellia Therapeutics by 49.5% during the 1st quarter. Federated Investors Inc. PA now owns 598,100 shares of the company’s stock worth $12,614,000 after purchasing an additional 198,100 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in Intellia Therapeutics during the 1st quarter worth about $3,374,000. Finally, Shellback Capital LP bought a new stake in Intellia Therapeutics during the 4th quarter worth about $2,343,000. 60.74% of the stock is owned by hedge funds and other institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.